Crown Energy AB (publ) today highlights a newly approved Italian clinical study in Rett syndrome where Accyourate’s smart garment platform will play a central role in collecting continuous, real-world physiological data in patients’ home environments.

The study, MirtaRett, coordinated by the University of Trieste and approved by the Italian Medicines Agency (AIFA), investigates whether mirtazapine may improve neurological and respiratory symptoms in patients with Rett syndrome, a rare, severe neurodevelopmental disorder primarily affecting females.

FROM EPISODIC CHECK UPS TO CONTINUOUS DIGITAL BIOMARKERS AT HOME

A key feature of MirtaRett is the integration of wearable-based digital biomarkers. Accyourate's solution, including innovative smart garments and a proprietary software platform enables continuous, non invasive 24 hour monitoring of parameters including respiratory pattern, apneas, ECG and heart rate dynamics, skin temperature, and more. The data is captured continuously in everyday life rather than only during brief clinic visits.

By generating objective, high resolution physiological data, the study aims to support researchers in assessing treatment effects, particularly in respiratory function, which is among the most critical and life threatening aspects of Rett syndrome.

MirtaRett is a non profit initiative involving 54 patients aged 5 to 40, across five Italian centers, divided into three age groups.

BUILDING ON CLINICAL EXPERIENCE IN RETT SYNDROME

Accyourate’s wearable approach has previously been used in Rett focused clinical studies, supporting the broader shift toward real world, longitudinal measurement in complex conditions. Continuous home monitoring can help clinicians and researchers better understand symptom patterns over time and evaluate whether interventions translate into meaningful physiological improvements.

Yoav Ben-Eli, CEO of Crown Energy AB, commented:

“MirtaRett is the type of real world clinical collaboration that demonstrates why smart wearables matter. When physiological signals can be captured continuously and comfortably, both in clinical settings and at home, researchers and clinicians gain a clearer, data driven view of treatment impact, especially in severe diseases where every improvement for patients and families is meaningful.”